CD38 and Miyoshi myopathy: Teclistamab was subsequently approved in the US for the treatment of adult patients with r/r MM who have received at least four prior lines of therapy (including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody) [98].